Neurocrine Biosciences, Inc. · NASDAQ:NBIX

Neurocrine Biosciences — Q1 2023 Earnings Presentation

41 slides from Neurocrine Biosciences's earnings presentation, May 3, 2023

  1. Slide 1: Advancing Life-Changing Discoveries in Neuroscience

    Advancing Life-Changing Discoveries in Neuroscience Q1 2023 Corporate Presentation May 3, 2023 Nasdaq: NBIX

  2. Slide 2: Safe Harbor Statement and Non-GAAP Financial Measures

    Safe Harbor Statement and Non-GAAP Financial Measures In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: the benefits to be derived from our

  3. Slide 3: Well Positioned for Sustained & Long-term Growth

    Well Positioned for Sustained & Long-term Growth 2023 Annual Net * Sales Guidance of ~600,000 are affected by TD in the U.S. $1.67B to $1.77B (~70% are undiagnosed) (Tardive Dyskinesia Only) R&D Focus Robust Multiple Compounds in Mid- to Late-Stage Studies • Neurology • Neuroendocrinology Pipeline S

  4. Slide 4: Q1 2023 Highlights and 2023 Key Milestones and Activities

    Q1 2023 Highlights and 2023 Key Milestones and Activities Q1 2023 / Recent Highlights 2023 Key Milestones and Activities ▪ INGREZZA® (valbenazine) Net Product Sales of $410M 2023 − Represents YoY Sales Growth of 36% vs. 2022 ▪ Potential sNDA Approval of Valbenazine for the Treatment of Chorea Associ

  5. Slide 5: Significant Milestones in the Second Half of 2023

    Significant Milestones in the Second Half of 2023 Valbenazine Crinecerfont NBI-921352 NBI-1065846 Chorea in Huntington Disease Congenital Adrenal Hyperplasia Focal Onset Seizures Anhedonia in MDD Phase 3 Data in Adult PDUFA and Pediatric Studies Phase 2 Data Phase 2 Data (August 20th) (Early Q4) (Q4

  6. Slide 6: Multiple Molecules and Mechanisms to Treat Intractable Diseases

    Multiple Molecules and Mechanisms to Treat Intractable Diseases NEUROLOGY NEUROENDOCRINOLOGY SCN8A Chorea in Tardive Focal Onset Developmental Parkinson’s Adrenal Huntington Dyskinesia Endometriosis Uterine Fibroids Insufficiency Seizures (FOS) and Epileptic Disease Disease (HD) (Adults) Encephalopa

  7. Slide 7: Strong Pipeline Momentum

    Strong Pipeline Momentum Phase 1 Phase 2 Phase 3 Partner Upcoming Milestones Neurology valbenazine* Chorea in Huntington Disease PDUFA Date = August 20th, 2023 valbenazine* Dyskinetic Cerebral Palsy Registrational Top-Line Data Expected in 2024 Reviewing Full Data Set from Phase 2 Study to NBI-82710

  8. Slide 8: Q1 2023 Financial Summary

    Q1 2023 Financial Summary $ Millions, Except Non-GAAP Earnings Per Share Item Q1 2023 Q1 2022 Highlights / Comments Revenue $420 $311 Q1 2023 INGREZZA Sales of $410M Driven by Record New - Product Sales, Net 415 305 Patient Starts - Collaboration Revenue 5 6 Non-GAAP R&D Expense $126 $90 Increase Dr

  9. Slide 9: 2023 INGREZZA Sales and Operating Expense Guidance

    2023 INGREZZA Sales (TD Indication Only) and Operating Expense Guidance Item ($ Millions) 2022 Actuals 2023 Guidance Range INGREZZA Net Product Sales1 $1,428 $1,670 - $1,770 GAAP R&D Expense2 $464 $550 - $580 Guidance Reiterated: Non-GAAP R&D Expense3 $406 $495 - $525 No Changes vs. Guidance Provide

  10. Slide 10: Corporate Sustainability

    Corporate Sustainability Our Purpose: Relieve Suffering for People with Great Needs, but Few Options Adhere to the highest Invest in our people Minimize our impact product quality and and communities on the environment safety standards Comprehensive Quality Industry-leading employee Improving profit

  11. Slide 11: Our Medicines, Our Patients

    © NEYROCRINE Our Medicines, Our Patients

  12. Slide 12: Commercial Products Fueling Pipeline Investment

    Commercial Products Fueling Pipeline Investment In the U.S. In the U.S. and EU * ‡ TARDIVE DYSKINESIA ENDOMETRIOSIS ADRENAL INSUFFICIENCY In Europe ‡ † PARKINSON'S DISEASE UTERINE FIBROIDS Congenital Adrenal Hyperplasia *Mitsubishi Tanabe Pharma Corporation (MTPC) has commercialization rights in Jap

  13. Slide 13: INGREZZA

    INGREZZA (valbenazine) capsules NEUROCRINE BIOSCIENCES

  14. Slide 14: INGREZZA Quarterly Net Sales Performance

    INGREZZA Quarterly Net Sales Performance ($MM) $450 Q1 2023 Sales of $410M Represents 36% Year-Over-Year Growth vs. Q1 2022 $410 $399 $400 $376 $350 $350 $301 $303 $300 $287 $265 $250 $200 Q2 '21 Q3 '21 Q4 '21 Q1 '22 Q2 '22 Q3 '22 Q4 '22 Q1 '23 14

  15. Slide 15: Substantial Impact on TD Patients and Care Partners

    Substantial Impact on TD Patients and Care Partners Movement disorder caused by prolonged use of antipsychotics and anti-nausea medications Uncontrollable, abnormal and repetitive movements >50% of patients experience meaningful emotional, social and psychological impact* Job Performance Low Self-Wo

  16. Slide 16: Nascent TD Market Presents Significant Opportunity

    Nascent TD Market Presents Significant Opportunity Approximately 30% of TD Patients Diagnosed E S T I M AT E D T O A F F E C T ~600,000 ✓ Only half of diagnosed patients receive treatment for TD with a VMAT2 inhibitor like INGREZZA people in the U.S. ~30% TD Diagnosed Increasing Antipsychotic Prescr

  17. Slide 17: Driving Long-Term Growth for INGREZZA

    Driving Long-Term Growth for INGREZZA Salesforce and distribution expansion INGREZZA and ONGENTYS offering greater access to neurology practices Investing in telemedicine capabilities Recommends patients with TD associated with antipsychotic therapy be treated with a VMAT2 inhibitor Patient outreach

  18. Slide 18: Once-Daily COMT Inhibitor for Parkinson's Disease

    ONGENTYS Is the 1st and Only FDA-Approved Once-Daily COMT Inhibitor for Parkinson’s Disease Provides Significant Reduction of Daily “Off” Time; Increase in Good “On” Time • Add-on treatment to levodopa/carbidopa prolongs clinical effects • One capsule, once a day treatment • Helps patients achieve m

  19. Slide 19: Neurology Pipeline

    © NEVROCRINE Neurology Pipeline

  20. Slide 20: sNDA for Valbenazine for Chorea in Huntington Disease Accepted by FDA

    Supplemental New Drug Application for Valbenazine for the Treatment of Chorea in Huntington Disease Accepted by FDA Valbenazine* Simple once-a-day treatment targeted for symptom control of chorea movements Safety profile consistent with and supported by extensive safety data in tardive dyskinesia In

  21. Slide 21: Valbenazine: Registrational Program in Dyskinetic Cerebral Palsy

    Valbenazine*: Registrational Program in Dyskinetic Cerebral Palsy Dyskinetic Cerebral Palsy (DCP) A form of cerebral palsy (CP) that affects ~15% of the approximately 500,000 to 1M people in the U.S. diagnosed with the disease. Can result in a range of developmental delays, physical difficulties and

  22. Slide 22: NBI-921352: Selective Nav1.6 Inhibitor in Ongoing Phase 2 Studies

    NBI-921352*: Selective Nav 1.6 Inhibitor in Ongoing Phase 2 Studies With Top-Line Data Expected in FOS in 2H 2023 Adult Focal Onset Seizures (FOS) Background SCN8A-DEE Background Also referred to as partial-onset seizures, Rare pediatric epilepsy with occurrence of these are the most common form of

  23. Slide 23: Neuroendocrinology Pipeline

    Neuroendocrinology Pipeline

  24. Slide 24: Classic Congenital Adrenal Hyperplasia (CAH)

    Classic Congenital Adrenal Hyperplasia (CAH) Rare Genetic Disorder Enzyme deficiency & reduced cortisol levels and excess androgen levels U.S. ~30,000* Europe ~50,000* Complex and Treatment Options Highly Stagnant for 60 Years Variable • Hormone replacement Symptoms • Do not address underlying issue

  25. Slide 25: Congenital Adrenal Hyperplasia Disease Mechanism

    Congenital Adrenal Hyperplasia Disease Mechanism Normal Homeostasis CAH Patients 25

  26. Slide 26: Crinecerfont Potentially Meets Challenges of the Standard of Care

    Crinecerfont* Potentially Meets Challenges of the Standard of Care Overtreatment Hypercortisolism Overtreatment Insulin Resistance Undertreatment Hypercortisolism Central Obesity Hyperandrogenism Osteoporosis Potentially Fatal Adrenal Crisis Insulin Resistance Impaired Glucose Tolerance CRINECERFONT

  27. Slide 27: Potential Paradigm Shift in the Treatment of CAH

    Potential Paradigm Shift in the Treatment of CAH With Top-Line Results Expected For Each Study in Early Q4 2023 Crinecerfont* Phase 3 Global Adult Registrational Study: Enrollment Complete Phase 3 Global Pediatric Registrational Study: Enrollment Complete Potent Orally Active Selective Well-Tolerate

  28. Slide 28: Neuropsychiatry Pipeline

    (5) NEUROCRINE BIOSCIENCES

  29. Slide 29: Valbenazine: Registrational Programs in Adjunctive Treatment of Schizophrenia

    Valbenazine*: Registrational Programs in Adjunctive Treatment of Schizophrenia With Top-Line Date from 1st Study in 2024 Adjunctive Treatment of Schizophrenia (ATS) Schizophrenia is one of the leading causes of disability worldwide, affecting up to 3.5M people in the U.S. alone. A serious, chronic m

  30. Slide 30: Potential First-in-Class Neuropsychiatry Programs

    Potential First-in-Class Neuropsychiatry Programs Takeda Collaborations Ongoing Clinical Programs in Phase 2 Studies Clinical Programs in Phase 2 Studies NBI-1065846* Anhedonia in Major Depressive Disorder Top-line Data Expected in Q4 2023 Inadequate Response to Treatment in NBI-1065845* Major Depre

  31. Slide 31: NBI-1065846: GPR139 Agonist

    NBI-1065846*: GPR139 Agonist Anhedonia in Major Depressive Disorder NBI-1065846 260 million+ people worldwide are Potent first-in-class investigational GPR139 agonist • Once weekly affected by major depressive disorder • Potential adjunctive treatment (MDD). GPR139 is an orphan receptor in the haben

  32. Slide 32: NBI-1065845: AMPA Potentiator

    NBI-1065845*: AMPA Potentiator Inadequate Response to Treatment NBI-1065845 in Major Depressive Disorder (MDD) Potent first-in-class AMPA potentiator ~1/3 of the 16 million+ people in the • Once daily U.S. who live with MDD do not respond • Potential adjunctive treatment to available antidepressants

  33. Slide 33: Luvadaxistat: D-Amino Acid Oxidase (DAAO) Inhibitor

    Luvadaxistat*: D-Amino Acid Oxidase (DAAO) Inhibitor Cognitive Impairment Associated with Luvadaxistat Schizophrenia (CIAS) Affects approximately 80% of the 3.5 Potent first-in-class DAAO inhibitor • Once daily million people in the U.S. diagnosed • No titration requirement with schizophrenia Hypofu

  34. Slide 34: Developing Novel Muscarinic Receptor Agonist Portfolio

    Developing Novel Muscarinic Receptor Agonist Portfolio Neurocrine Biosciences Advancing Muscarinic Portfolio Clinical studies, include: ➢ Initiated Phase 2 placebo-controlled study of NBI-1117568*, a selective M4 agonist, as a potential treatment for schizophrenia ✓ NBI-1117568 offers the potential

  35. Slide 35: Well Positioned for Sustained & Long-term Growth

    Well Positioned for Sustained & Long-term Growth 2023 Annual Net * Sales Guidance of ~600,000 are affected by TD in the U.S. $1.67B to $1.77B (~70% are undiagnosed) (Tardive Dyskinesia Only) R&D Focus Robust Multiple Compounds in Mid- to Late-Stage Studies • Neurology • Neuroendocrinology Pipeline S

  36. Slide 36: GAAP to Non-GAAP Reconciliations

    GAAP to Non-GAAP Reconciliations neurocrine.com

  37. Slide 37: Condensed Consolidated Statements of Operations

    NEUROCRINE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) Three Months Ended March 31, (in millions, except per share data) 2023 2022 Revenues: Product sales, net $ 4153 $ 305.0 Collaboration revenue SA 56 Total revenues 4204 310.6 Operating expenses: Cost of revenues

  38. Slide 38: Condensed Consolidated Balance Sheets

    NEUROCRINE BIOSCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) March 31, December 31, (in millions) 2023 2022 Cash, cash equivalents and debt securities available-for-sale $ 8946 §$ 989.3 Other current assets 538.2 464.2 Total current assets 1,432.8 1,453.5 Deferred tax assets 337.4

  39. Slide 39: Reconciliation of GAAP to Non-GAAP Financial Results

    NEUROCRINE BIOSCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS (unaudited) Three Months Ended March 31, (in millions, except per share data) 2023 2022 GAAP net (loss) income $ (76.6) $ 13.9 Adjustments: Stock-based compensation expense - R&D 13.8 12.5 Stock-based compensation expe

  40. Slide 40: Reconciliation of GAAP to Non-GAAP Expenses

    NEUROCRINE BIOSCIENCES NEUROCRINE BIOSCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP EXPENSES (unaudited) Three Months Ended March 31, in millions) — 203202 GAAP cost of revenues $ 85 $ 46 Adjustments: Non-cash amortization related to acquired intangible assets 09 ‘Non-GAAP cost of revenues 76 $ 4

  41. Slide 41: Advancing Life-Changing Discoveries in Neuroscience

    Advancing Life-Changing Discoveries in Neuroscience Q1 2023 Corporate Presentation May 3, 2023 Nasdaq: NBIX

Neurocrine Biosciences — Q1 2023 Earnings Presentation on 6ix